OBJECTIVE: Patients with neurofibromatosis type 1 (NF1) are predisposed to visceral neurofibromas, some of which can progress to premalignant atypical neurofibromas (ANFs) and malignant peripheral nerve sheath tumors (MPNSTs). Though subtotal resection of ANF may prevent malignant transformation and thus deaths with no neural complications, local recurrences require reoperation. The aim of this study was to assess the surgical morbidity associated with marginal resection of targeted ANF nodules identified via preoperative serial volumetric MRI and 18F-FDG-PET imaging. METHODS: The authors analyzed clinical outcomes of 16 NF resections of 21 tumors in 11 NF1 patients treated at the NIH Clinical Center between 2008 and 2018. Preoperative volumetric growth rates and 18F-FDG-PET SUVMax (maximum standardized uptake value within the tumor) of the target lesions and any electromyographic or nerve conduction velocity abnormalities of the parent nerves were measured and assessed in tandem with postoperative complications, histopathological classification of the resected tumors, and surgical margins through Dunnett's multiple comparisons test and t-test. The surgical approach for safe marginal resection of ANF was also described. RESULTS: Eleven consecutive NF1 patients (4 male, 7 female; median age 18.5 years) underwent 16 surgical procedures for marginal resections of 21 tumors. Preoperatively, 13 of the 14 (93%) sets of serial MRI studies and 10 of the 11 (91%) 18F-FDG-PET scans showed rapid growth (≥ 20% increase in volume per year) and avidity (SUVMax ≥ 3.5) of the identified tumor, respectively (median tumor size 48.7 cm3; median growth rate 92% per year; median SUVMax 6.45). Most surgeries (n = 14, 88%) resulted in no persistent postoperative parent nerve-related complications, and to date, none of the resected tumors have recurred. The median length of postoperative follow-up has been 2.45 years (range 0.00-10.39 years). Histopathological analysis confirmed significantly greater SUVMax among the ANFs (6.51 ± 0.83, p = 0.0042) and low-grade MPNSTs (13.8, p = 0.0001) than in benign neurofibromas (1.9). CONCLUSIONS: This report evaluates the utility of serial imaging (MRI and 18F-FDG-PET SUVMax) to successfully detect ANF and demonstrates that safe, fascicle-sparing gross-total, extracapsular resection of ANF is possible with the use of intraoperative nerve stimulation and microdissection of nerve fascicles.
OBJECTIVE:Patients with neurofibromatosis type 1 (NF1) are predisposed to visceral neurofibromas, some of which can progress to premalignant atypical neurofibromas (ANFs) and malignant peripheral nerve sheath tumors (MPNSTs). Though subtotal resection of ANF may prevent malignant transformation and thus deaths with no neural complications, local recurrences require reoperation. The aim of this study was to assess the surgical morbidity associated with marginal resection of targeted ANF nodules identified via preoperative serial volumetric MRI and 18F-FDG-PET imaging. METHODS: The authors analyzed clinical outcomes of 16 NF resections of 21 tumors in 11 NF1patients treated at the NIH Clinical Center between 2008 and 2018. Preoperative volumetric growth rates and 18F-FDG-PET SUVMax (maximum standardized uptake value within the tumor) of the target lesions and any electromyographic or nerve conduction velocity abnormalities of the parent nerves were measured and assessed in tandem with postoperative complications, histopathological classification of the resected tumors, and surgical margins through Dunnett's multiple comparisons test and t-test. The surgical approach for safe marginal resection of ANF was also described. RESULTS: Eleven consecutive NF1patients (4 male, 7 female; median age 18.5 years) underwent 16 surgical procedures for marginal resections of 21 tumors. Preoperatively, 13 of the 14 (93%) sets of serial MRI studies and 10 of the 11 (91%) 18F-FDG-PET scans showed rapid growth (≥ 20% increase in volume per year) and avidity (SUVMax ≥ 3.5) of the identified tumor, respectively (median tumor size 48.7 cm3; median growth rate 92% per year; median SUVMax 6.45). Most surgeries (n = 14, 88%) resulted in no persistent postoperative parent nerve-related complications, and to date, none of the resected tumors have recurred. The median length of postoperative follow-up has been 2.45 years (range 0.00-10.39 years). Histopathological analysis confirmed significantly greater SUVMax among the ANFs (6.51 ± 0.83, p = 0.0042) and low-grade MPNSTs (13.8, p = 0.0001) than in benign neurofibromas (1.9). CONCLUSIONS: This report evaluates the utility of serial imaging (MRI and 18F-FDG-PET SUVMax) to successfully detect ANF and demonstrates that safe, fascicle-sparing gross-total, extracapsular resection of ANF is possible with the use of intraoperative nerve stimulation and microdissection of nerve fascicles.
Entities:
Keywords:
ANF = atypical neurofibroma (neurofibroma with nuclear atypia); ANNUBP = atypical neurofibromatous neoplasm of uncertain biological potential; EMG = electromyographic; MPNST = malignant peripheral nerve sheath tumor; NCI = National Cancer Institute; NCV = nerve conduction velocity; NF1 = neurofibromatosis type 1; NIH = National Institutes of Health; SUVMax = maximum SUV within the tumor; atypical neurofibroma; hgMPNST = high-grade MPNST; lgMPNST = low-grade MPNST; marginal margin; neurofibromatosis 1; peripheral nerve; resection; surgery
Authors: Christine S Higham; Eva Dombi; Aljosja Rogiers; Sucharita Bhaumik; Steven Pans; Steve E J Connor; Markku Miettinen; Raf Sciot; Roberto Tirabosco; Hilde Brems; Andrea Baldwin; Eric Legius; Brigitte C Widemann; Rosalie E Ferner Journal: Neuro Oncol Date: 2018-05-18 Impact factor: 12.300
Authors: Elina Uusitalo; Matti Rantanen; Roope A Kallionpää; Minna Pöyhönen; Jussi Leppävirta; Heli Ylä-Outinen; Vincent M Riccardi; Eero Pukkala; Janne Pitkäniemi; Sirkku Peltonen; Juha Peltonen Journal: J Clin Oncol Date: 2016-02-29 Impact factor: 44.544
Authors: Nicholas M Bernthal; Angelica Putnam; Kevin B Jones; David Viskochil; R Lor Randall Journal: J Surg Oncol Date: 2014-08-11 Impact factor: 3.454
Authors: Michael M Safaee; Russ Lyon; Nicholas M Barbaro; Dean Chou; Praveen V Mummaneni; Philip R Weinstein; Cynthia T Chin; Tarik Tihan; Christopher P Ames Journal: J Neurosurg Spine Date: 2016-07-29
Authors: Miriam A Bredella; Martin Torriani; Francis Hornicek; Hugue A Ouellette; William E Plamer; Ziv Williams; Allan J Fischman; Scott R Plotkin Journal: AJR Am J Roentgenol Date: 2007-10 Impact factor: 3.959
Authors: Mohamad Farid; Elizabeth G Demicco; Roberto Garcia; Linda Ahn; Pamela R Merola; Angela Cioffi; Robert G Maki Journal: Oncologist Date: 2014-01-27
Authors: Brian P Curry; Reinier Alvarez; Brigitte C Widemann; Matthew Johnson; Piyush K Agarwal; Tanya Lehky; Vladimir Valera; Prashant Chittiboina Journal: Oper Neurosurg (Hagerstown) Date: 2022-02-01 Impact factor: 2.817
Authors: Enrico Martin; Ritchie T J Geitenbeek; J Henk Coert; David F Hanff; Laura H Graven; Dirk J Grünhagen; Cornelis Verhoef; Walter Taal Journal: Neuro Oncol Date: 2021-04-12 Impact factor: 12.300
Authors: Caitlin Tydings; Pavel Yarmolenko; Miriam Bornhorst; Eva Dombi; John Myseros; Robert Keating; James Bost; Karun Sharma; AeRang Kim Journal: Neurooncol Adv Date: 2021-08-18
Authors: Ritch T J Geitenbeek; Enrico Martin; Laura H Graven; Martijn P G Broen; Monique H M E Anten; Jochem A J van der Pol; Cornelis Verhoef; Walter Taal Journal: J Neurooncol Date: 2022-01-13 Impact factor: 4.130